PPIB and metabolic dysfunction-associated steatotic liver disease: This is also in line with our previous studies showing that pan-cyclophilin inhibitors NV556 and CRV431 significantly reduced HCC tumor burden in NAFLD/NASH mouse models and suggests that specifically CypD inhibition was at least in part responsible for this effect.